Monoclonal Antibody Therapeutics Market to Surpass US$ 174.2 Billion Threshold by 2026

The global monoclonal antibody therapeutics market by Source (Human, Humanized, Chimeric, and Others), by Therapeutic Application (Oncology, Autoimmune Diseases, Infectious Diseases, Hematological Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Specialty Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 95,560.5 million in 2017, and is projected to exhibit a CAGR of 6.9% over the forecast period (2018–2026).

Robust pipeline, success of monoclonal antibodies such as Humira (AbbVie, Inc.) and therapeutic advantages offered by these drugs over existing medications are expected to boost growth of the global monoclonal antibody therapeutics market. Moreover, key players in the market are focused on research and development of new monoclonal antibodies in order to enhance their market share. For instance, in 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to avelumab (BAVENCIO, EMD Serono, Inc.) for the treatment of a rare disease, Metastatic Merkel Cell Carcinoma (MCC).

Request Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/2403

Similarly, in 2017, the U.S FDA granted accelerated approval to immunotherapy product- TECENTRIQ (atezolizumab) for the treatment of people with locally-advanced or metastatic urothelial carcinoma (mUC). In 2015, Sanofi and Regeneron Pharmaceuticals, Inc. entered into a strategic collaboration to develop and commercialize new antibody cancer treatment (SAR439684) in the oncology market. Sanofi and Regeneron are developing an antibody-based cancer therapy- REGN2810 (SAR439684) for the treatment of cutaneous squamous cell carcinoma, which is currently in phase 2 clinical trials.

Browse 26 Market Data Tables and 37 Figures spread through 187 Pages and in-depth TOC on Global Monoclonal Antibody Therapeutics Market, by Source (Human, Humanized, Chimeric, and Others), by Therapeutic Application (Oncology, Autoimmune Diseases, Infectious Diseases, Hematological Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Specialty Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2026.

Increasing product launches and regulatory support for the treatment of rare diseases is expected to support growth of the monoclonal antibody therapeutics market. Several companies have received the U.S FDA approvals for drugs used in treatment of diseases ranging from cancers to rare diseases. For instance, in August 2018, Kyowa Hakko Kirin Co., Ltd received the U.S. FDA approval for Poteligeo (mogamulizumab-kpkc) for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. Moreover, in August 2018, Shire plc. received the U.S. FDA approval for TAKHZYRO (lanadelumab-flyo) injection for a rare disease hereditary angioedema (HAE) in patients 12 years of age and older. Increasing focus of key players for developing monoclonal antibodies for various cancers and rare diseases is expected to boost the global monoclonal antibody therapeutics market growth over the forecast period.

Request Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2403

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Author:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods.

This release was published on openPR.